Kelley Kenneth J 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Mar 19, 2020
Insider Transaction Report
Form 4
Kelley Kenneth J
Director
Transactions
- Purchase
Common Stock
[F1]2020-03-19$14.19/sh+17,543$248,933→ 242,467 total - Purchase
Common Stock
[F2]2020-03-19$14.25/sh+17,543$249,982→ 260,010 total - Purchase
Common Stock
[F3]2020-03-19$14.24/sh+17,543$249,781→ 277,553 total
Footnotes (3)
- [F1]Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $14.11 to $14.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- [F2]Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $14.23 to $14.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- [F3]Represents a weighted average purchase price per share. These shares were purchased at prices ranging from $14.15 to $14.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
Signature
/s/ James R. Oehler as attorney-in-fact for Kenneth J. Kelley|2020-03-19